Research and development is the lifeblood of the pharmaceutical industry. But in the past few years, many of the world\'s large pharmaceutical companies seem to be somewhat weak. Recently the number of new drugs launched in the global market has dropped sharply. The cost of developing innovative drugs has risen to such an extent that is can not be maintained. The problem is not the number of new drug, but whether these drugs are really novel and useful. Since 2000, only a small number of new drugs to prevent and cure diseases - especially cancer treatment - have entered the market. However, critics point out that only one-third of the drugs that have been launched in the market over the past few years are among the best in the same class. The rest are similar drugs, roughly the same as the existing drugs, in the same way to deal with the same problem.
阿摩線上測驗
登入